News

Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at hscora@ouhsc.edu so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, July 16, 2018

Harold Hamm Diabetes Center (HHDC) - Please mark your calendar for the 15th Annual Harold

Hamm Diabetes Center Research Symposium.  This event will be held on Friday, November 16, 2018 

at the Samis Education Center at Children’s Hospital in Oklahoma City. Deadline for abstracts will be

announced later this summer.  Additional details will be posted on http://haroldhamm.org/  Questions? 

Please email Katie-Hoefling@ouhsc.edu.

 

 

NIH NOTICES

 

NIH Synchronizes Institutional Delegations and Now Allows Decimals in Effort Reporting Field

in Research Performance Progress Reports (RPPR) (NOT-OD-18-202)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-202.html

 

Notice of Intent to Publish a Funding Opportunity Announcement for Reproductive Medicine Clinical

Trials Program (R01 Clinical Trial Required) (NOT-HD-18-012)
https://grants.nih.gov/grants/guide/notice-files/NOT-HD-18-012.html

 

Notice of Modification to a Page Limitation in PAR-18-266 "Centers of Biomedical Research Excellence

(COBRE)(P20)" (NOT-GM-18-037)
https://grants.nih.gov/grants/guide/notice-files/NOT-GM-18-037.html

 

Notice of Modification to a Page Limitation in PAR-18-264 "Limited Competition: Renewal of Centers of

Biomedical Research Excellence (COBRE)(P20)" (NOT-GM-18-038)
https://grants.nih.gov/grants/guide/notice-files/NOT-GM-18-038.html

 

Notice of NIMHD Participation in PA-18-343: "Academic Research Enhancement Award (R15 Clinical

Trial Required)" (NOT-MD-18-009)
https://grants.nih.gov/grants/guide/notice-files/NOT-MD-18-009.html

 

Notice of Pre-Application Webinar for RFA-CA-18-025 Cooperative Human Tissue Network (CHTN)

(NOT-CA-18-089)
https://grants.nih.gov/grants/guide/notice-files/NOT-CA-18-089.html

 

Updates for PAR-16-098 "Cooperative Research Agreements Related to World Trade Center Health

Program (U01)" (NOT-OH-18-009)
https://grants.nih.gov/grants/guide/notice-files/NOT-OH-18-009.html

 

 

Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least one month prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.

 

NIH DEADLINES

 

Halting TB Transmission in HIV-Endemic and Other High-Transmission Settings (R01 Clinical Trial

Not Allowed) (RFA-AI-18-037) – Deadline December 5, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-037.html  

 

The National Health and Aging Trends Study (U01 Clinical Trial Not Allowed) (RFA-AG-19-019)

Deadline October 1, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-19-019.html

 

NIDCD Hearing Healthcare for Adults: Improving Access and Affordability (R21/R33 Clinical Trials

Optional) (RFA-DC-19-001) – Deadline October 4, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-19-001.html

 

NIMH Career Enhancement Award to Advance Autism Services for Adults and Transition-Age Youth

(K18 Clinical Trials Not Allowed) (RFA-MH-19-100) – Deadline October 22, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-19-100.html

 

NIMH Career Enhancement Award to Advance Autism Services for Adults and Transition-Age Youth

(K18 Clinical Trials Required) (RFA-MH-19-101) – Deadline October 22, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-19-100.html

 

Novel Approaches for Characterizing Exposure and Response to Engineered Nanomaterials

(R43 Clinical Trials Not Allowed) (RFA-ES-18-008) – September 11, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-18-008.html

 

Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)

(RFA-ES-18-002) – December 19, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-18-002.html

 

 

OTHER SOURCES

 

American Lung Association (ALA) – Lung Cancer Discovery Award – Letter of Intent Deadline

October 3, 2018

http://www.lung.org/our-initiatives/research/awards-and-grant-funding/

 

ALA – Allergic Respiratory Diseases Award – Deadline December 13, 2018

http://www.lung.org/our-initiatives/research/awards-and-grant-funding/

 

ALA – Innovation Award – Deadline December 13, 2018

http://www.lung.org/our-initiatives/research/awards-and-grant-funding/

 

ALA – Catalyst Award – Deadline December 13, 2018

http://www.lung.org/our-initiatives/research/awards-and-grant-funding/

 

ALA – Public Policy Research Award – Deadline December 13, 2018

http://www.lung.org/our-initiatives/research/awards-and-grant-funding/

 

ALA – Dalsemer Award – Deadline December 13, 2018

http://www.lung.org/our-initiatives/research/awards-and-grant-funding/

 

 

New Clinical Study Opportunities

***************************************************************

Please note this is NOT a solicitation for study subjects

***************************************************************

Several Pharmaceutical companies are looking for Principal Investigators to participate in the

following clinical studies:

  • A PHASE 1-2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF ORAL

EFT508 IN SUBJECTS WITH HEMATOLOGICAL MALIGNANCIES non-GCB DLBCL

  • Phase 2 Study Is Exploring The Efficacy And Safety Of Various Doses Of Ponatinib

For The Treatment Of Chronic Myeloid Leukemia (CML)

  • Phase III Study Of An Investigational Disease-Modifying, Angiogenic Gene Therapy 

To Treat Patients With Refractory Angina Due To Myocardial Ischemia (00115914)

  • Treating Pediatrics with Secondary Hyperparathyroidism in Chronic Kidney Disease

Undergoing Hemodialysis (Phase 3) 20140315

Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more information

on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be

routed to the Office of Research Administration.

 

 

Print

Name:
Email:
Subject:
Message:
x